Type-II_JJ
estrogen_NN
binding_NN
sites_NNS
in_IN
a_DT
lymphoblastoid_JJ
cell_NN
line_NN
and_CC
growth-inhibitory_JJ
effect_NN
of_IN
estrogen_NN
,_,
anti-estrogen_NN
and_CC
bioflavonoids_NNS
._.

Type-II_JJ
estrogen-binding_JJ
sites_NNS
-LRB-_-LRB-
type-II_JJ
EBS_NNS
-RRB-_-RRB-
have_VBP
been_VBN
demonstrated_VBN
in_IN
the_DT
human_JJ
lymphoblastoid_JJ
cell_NN
line_NN
IM-9_NN
using_VBG
a_DT
whole-cell_JJ
assay_NN
with_IN
-LRB-_-LRB-
6,7-3H_NN
-RRB-_-RRB-
estradiol_NN
-LRB-_-LRB-
3H-E2_NN
-RRB-_-RRB-
as_IN
tracer_NN
._.

Competition_NN
analysis_NN
showed_VBD
that_IN
the_DT
anti-estrogen_JJ
tamoxifen_NN
and_CC
the_DT
flavonoids_JJ
quercetin_NN
and_CC
rutin_NN
competed_VBD
for_IN
-LRB-_-LRB-
3H_NN
-RRB-_-RRB-
-_CC
E2_NN
binding_NN
to_TO
type-II_JJ
EBS_NNS
._.

Growth_NN
experiments_NNS
demonstrated_VBD
that_IN
diethylstilbestrol_NN
-LRB-_-LRB-
DES_NN
-RRB-_-RRB-
tamoxifen_NN
-LRB-_-LRB-
TAM_NN
-RRB-_-RRB-
,_,
quercetin_NN
and_CC
rutin_NN
exerted_VBD
a_DT
reversible_JJ
dose-dependent_JJ
inhibition_NN
of_IN
cell_NN
proliferation_NN
in_IN
the_DT
range_NN
of_IN
concentrations_NNS
between_IN
10_CD
nM_NN
and_CC
10_CD
microM_NN
._.

The_DT
relative_JJ
binding_NN
affinity_NN
of_IN
quercetin_NN
,_,
rutin_NN
,_,
DES_NN
and_CC
TAM_NN
for_IN
type-II_JJ
EBS_NNS
correlated_VBD
well_RB
with_IN
their_PRP$
potency_NN
as_IN
cell_NN
growth_NN
inhibitors_NNS
._.

Moreover_RB
,_,
hesperidin_NN
,_,
a_DT
flavonoid_NN
which_WDT
does_VBZ
not_RB
bind_VB
to_TO
type-II_JJ
EBS_NNS
,_,
was_VBD
ineffective_JJ
in_IN
inhibiting_VBG
cell_NN
growth_NN
._.

Cell-cycle_JJ
analysis_NN
showed_VBD
that_IN
the_DT
growth-inhibitory_JJ
effect_NN
of_IN
DES_NNP
,_,
TAM_NNP
or_CC
quercetin_NN
was_VBD
due_JJ
to_TO
a_DT
blocking_VBG
effect_NN
in_IN
the_DT
G0-G1_JJ
phases_NNS
._.

Our_PRP$
results_NNS
suggest_VBP
that_IN
high_JJ
estrogen_NN
and_CC
anti-estrogen_JJ
concentrations_NNS
and_CC
flavonoids_NNS
may_MD
regulate_VB
IM-9_NN
cell_NN
growth_NN
through_IN
a_DT
common_JJ
mechanism_NN
involving_VBG
a_DT
binding_NN
interaction_NN
with_IN
type-II_JJ
EBS_NNS
._.

